Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 7/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30749607 | 0.86 | MAP4K1 (0.47) | MAP4K1ALDH1A1CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL27170740 | 0.86 | MAP4K1 (0.47) | MAP4K1ALDH1A1CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL25369137 | 0.81 | MAPT (0.44) | MAP4K1ALDH1A1CYP11B1CYP11B2L3MBTL1 | |
| SCHEMBL25368535 | 0.81 | MAP4K1 (0.51) | MAP4K1ALDH1A1CYP11B1CYP11B2NR3C1 | |
| SCHEMBL27170710 | 0.81 | MAP4K1 (0.45) | MAP4K1ALDH1A1CYP11B1CYP11B2NR3C1 | |
| SCHEMBL30749628 | 0.81 | MAP4K1 (0.45) | MAP4K1ALDH1A1CYP11B1CYP11B2NR3C1 | |
| SCHEMBL25367846 | 0.79 | NR3C1 (0.54) | MAP4K1CYP11B1CYP11B2NR3C1PGR | |
| SCHEMBL29493820 | 0.78 | NR3C1 (0.47) | MAP4K1CYP11B1CYP11B2NR3C1PGR | |
| SCHEMBL25366652 | 0.78 | NR3C1 (0.47) | MAP4K1CYP11B1CYP11B2NR3C1PGR | |
| SCHEMBL1541841 | 0.76 | ALDH1A1 (0.54) | MAP4K1ALDH1A1CYP11B1CYP11B2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-03-14 | — | — | US | disclosed |
| CN-116600801-A | HSD17B13 inhibitors and uses thereof | FL2022-001公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-4221701-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022072491-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083853-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | MAP4K1 3312/4885ALDH1A1 247/4885CYP11B1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.